About Us

about_us_sm
Our mission: to help people living with Parkinson’s to live well today.

News

Support Us

Great Lakes NeuroTechnologies Awarded Patent for Technology to Assess Parkinson’s Disease

By Great Lakes NeuroTechnologies, The Sacramento Bee, www.sacbee.com

VALLEY VIEW, Ohio, March 9, 2012 – /PRNewswire/ – Great Lakes NeuroTechnologiesannounced today that they have received allowance of claims from the U.S. Patent Office for an application covering their Movement Disorder Monitoring System and Method for quantitative assessment of motor symptoms associated with movement disorders. The claims cover a system and method of wireless patient-worn motion sensors that assess tremor, bradykinesia, rigidity, and dyskinesias associated with diseases like Parkinson’s and essential tremor.  This innovative medical technology has applications for both in-clinic and home-based patient care, optimizing programming for deep brain stimulation, and providing quantitative endpoints to determine efficacy of clinical trials.  When used in telemedicine applications, physicians utilize a web interface to track symptom responses and fluctuations.

To address the growing market need for standardized and ambulatory assessment of movement disorders, Great Lakes NeuroTechnologies has been committed to the commercialization of theKinesia and Kinesia HomeView medical technology platforms since 2003.  “The allowance of our patent claims continues a successful commercialization path for our Parkinson’s assessment systems intended to help physicians maximize therapeutic benefits and ultimately improve patient quality of life,” says Joseph P. Giuffrida, PhD, President. “Great Lakes NeuroTechnologies is uniquely positioned in the movement disorders market as a world leader in medical device development and manufacture of technologies to standardize, automate, and remotely capture patient assessments. This heightened intellectual property position builds on and protects our previous commercialization efforts and continued market growth.”  Dr. Giuffrida also thanked theNational Institute of Neurological Disorders and Stroke and the National Institute on Aging for their continued support of these technologies.

Read more here.

 

This entry was posted in Blog, News. Bookmark the permalink.
[SINGLE POST]